Cardiol Therapeutics Inc. (CRDL)
Upgrades & Downgrades
Latest CRDL news
Cardiol Therapeutics appoints Teri Loxam and CFO Chris Waddick to its board of directors
19 May 2022
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc., the clinical-stage life sciences company, said it has appointed Teri Loxam and its chief financial officer Chris Waddick to serve as board directors,...
Cardiol Therapeutics receives US FDA authorization for Phase II study of CardiolRx for recurrent per...
17 May 2022
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc announced that the US Food and Drug Administration has authorized its Investigational New Drug Application to start its Phase II open-label pilot study...
Cardiol Therapeutics looks ahead to busy 2022 as it advances new treatment options for cardiovascula...
24 March 2022
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc CEO David Elsley told investors that the clinical-stage life sciences company is “well positioned” to pursue the development of new treatment options f...
Cardiol Therapeutics says Jennifer M. Chao has been appointed as director of the company
15 March 2022
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc has announced that Jennifer M. Chao has been appointed as a director of the company, effective immediately.
Cardiol Therapeutics receives clearance to expand eligible patient group for its LANCER study
1 March 2022
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc announced it has received clearance from the US Food and Drug Administration and its counterparts in Brazil and Mexico to modify the inclusion criteria...
Cardiol Therapeutics appoints three new members to its Scientific Advisory Board
19 January 2022
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc has appointed three new cardiovascular experts to its Scientific Advisory Board. The clinical-stage life sciences company welcomed Dr Paul Ridker, Dr B...
Cardiol Therapeutics raises US$50M to advance research and clinical development initiatives
5 November 2021
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc announced it has closed a US$50 million public offering to advance its research and clinical development programs. The clinical-stage biotechnology com...
Cardiol Therapeutics receives Health Canada approval for Phase II trial of CardiolRx
25 October 2021
Cardiol Therapeutics Inc announced it has received Health Canada approval to proceed with its Phase II trial of lead drug CardiolRx for acute myocarditis. The multi-center, double-blind, randomized, a...